HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
about
Molecular biology of lung cancerMolecular biology of lung cancer: clinical implicationsRole of HER2 in NSCLCAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceHER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approachesCIViC databaseTargeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsAnalysis of compound synergy in high-throughput cellular screens by population-based lifetime modelingSurvival and death signals can predict tumor response to therapy after oncogene inactivationA comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanTargeted therapy in NSCLC driven by HER2 insertionsAnti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsPrevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung AdenocarcinomaTargetable "driver" mutations in non small cell lung cancer.A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.New targetable oncogenes in non-small-cell lung cancer.Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.How genetically engineered mouse tumor models provide insights into human cancersSensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system.Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.Personalized therapies in the cancer "omics" eraQuinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).Other signalization targets.HER2 and lung cancer.Afatinib and lung cancer.
P2860
Q24606677-DED39252-CD48-43A0-B30F-4CF2E25C13DCQ24610335-2A12AC77-A935-48F4-9BA4-ED2403F43994Q26781683-807D38C8-A169-4DF1-8228-6E40913B06C9Q26797471-7A85D5AE-8989-4098-9F31-073AA174057FQ26866534-98AB0C70-6E8A-4461-BA31-26E4B606851EQ27612411-18AB5637-CD90-47F3-B083-A23FC2D1D99CQ27853154-BCC907D8-4D24-425B-BE70-E97D682A9FEDQ28472663-8FB79FC8-3EC2-48DC-ABA2-F9444801A8C9Q30574736-90FDE2DD-4893-4A93-BAA1-2EB81EBCA829Q33605906-C04ED96A-728B-42F1-896E-AFA3C1618F4DQ33823191-12F5DFC2-0C74-4DE4-901D-6B06A05618AEQ35024472-D9E1B3A0-632D-4205-AE84-90185F661CD7Q35136424-EEFBCACC-865B-4AC2-80D9-570E09EE8126Q35196603-B8F3E29A-1A03-4CCC-89CB-39484514363EQ35200528-310A2312-D3FE-41D7-9D0B-F3A59CF4BD7FQ35623056-8FA75E40-EF6A-4772-A7F8-7864A740D5B4Q35671830-DBDA0A6C-1C62-4A92-A86D-3D6F5A0A81F9Q35737325-F046BE37-EE6E-46A6-886F-6F213D952BF7Q35782291-72568EBB-0E73-4C42-A376-C66D4DD5F04CQ36177675-813586C9-989F-4003-9660-772C861E31DFQ36336795-CA24BA9D-5968-4526-B6E5-21743CA4CCF5Q36346641-B98D2239-487A-4B1D-AC2A-39153E77BBA1Q36495936-FDE10E89-B21F-4945-B614-6E522CCC5DC7Q36544650-20CEECE0-E3F2-400C-8EA5-5C06B420B38CQ36547123-B13142C7-F1BD-4E12-8817-9BD93C94FB6AQ36660677-20C126DF-1C74-4DE5-B23B-860438EEF89FQ36694995-7FDF29E9-613A-4580-951C-068A2C8621C7Q36785721-7B638B18-F352-4C0D-85B6-2F1A5138099AQ36910173-D41BEDC2-0A51-4654-B6DE-67DEC2E606F5Q36927538-98844A12-BE15-4B59-907E-56A9075572A7Q36942619-1710636A-BC04-4D82-9AD4-DEF1932CD567Q37065678-59F91297-73FC-4740-9490-97A2B9867E06Q37229404-A770B9DE-4026-4156-9211-C60850D1A5C5Q37376100-58804929-E6E0-4859-AFEB-2743E21433C1Q37398636-04AC1554-2968-4A78-B401-417D1955C38CQ37776547-5C14D649-BD5A-43B5-B2D3-EF41EBFCFE51Q37992086-C27FFC6A-5364-4931-A8A7-38162C70F65EQ38073157-1E118F4F-6B76-4DC2-951D-CC714D934350Q38153447-138F3017-4B22-41ED-B4E8-E195D94DBB8BQ38270627-1418A51B-0F98-454A-8BAB-C438C6A4D0F2
P2860
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@ast
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@en
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@nl
type
label
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@ast
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@en
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@nl
altLabel
HER2YVMA drives rapid developm ...... rapamycin combination therapy
@en
prefLabel
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@ast
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@en
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@nl
P2093
P2860
P50
P3181
P356
P1476
HER2YVMA drives rapid developm ...... rapamycin combination therapy.
@en
P2093
Christa L Borgman
Flavio Solca
Geoffrey I Shapiro
Hongbin Ji
Kathleyn A Brandstetter
Liang Chen
Lucian R Chirieac
Maria G Raso
Masaya Takahashi
P2860
P304
P3181
P356
10.1073/PNAS.0808930106
P407
P577
2009-01-02T00:00:00Z